Chad Briscoe on emerging trends and updates in the biomarker area

Biomarkers Interviews Regulated bioanalysis

During the American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 2025 conference, Bioanalysis Zone caught up with industry experts across numerous disciplines to discuss their involvement with AAPS and their research. In this interview, we spoke to Chad Briscoe about regulatory updates and emerging trends in the biomarker area, as well as discuss his BioTalk Unzipped podcast!

Disclaimer: The opinions expressed in this interview are those of the author and do not necessarily reflect the views of Bioanalysis Zone or Taylor & Francis Group.

Interview questions:

  1. What is your role at Celerion?
  2. Independent of your role at Celerion, you’ve been doing some podcasting – could you share a little bit about your BioTalk Unzipped podcast?
  3. What discussions are you most excited for this year?
  4. What emerging trends have you noticed in the biomarker area?
  5. With the FDA issuing the long-awaited guidance on bioanalytical method validation for biomarkers (BMVB), which replaces the 2018 FDA BMV, how would you recommend staying up-to-date with evolving regulations?
  6. Are there any new technologies or platforms you anticipate becoming more popular in 2026?
  7. What do you think the bioanalytical lab will look like in 10 years time?
Meet the speaker

Chad Briscoe
Executive Vice President of Global Bioanalytical Services
Celerion (NE, USA)

Dr Briscoe is an innovative, solutions focused bioanalytical thought leader working with partners every day to bring new drugs to market faster. In his various roles at BioAgilytix, Dr Briscoe was responsible for driving short- long-term solutions for sponsors through a highly collaborative strategy involving sales operations and science. He worked with pharmaceutical companies around the world to help them better plan for and execute the bioanalytical and biomarker aspects of their clinical trials. In his current role at Celerion, he leverages his nearly 25 years of experience as a Bioanalytical Scientist and Executive to bring practical solutions to the ever-increasing complexity of clinical trials. He is a recognized global expert and thought leader in areas such as biomarker analysis, LC/MS/MS bioanalysis and analytical instrument qualification. He has been a frequent speaker at global and regional conferences on such topics. Dr Briscoe holds a PhD from the University of Nebraska (NE, USA) where he studied protein binding interactions using immunoaffinity chromatography. He also has a master’s degree from the University of Michigan (MI, USA) and bachelor’s degree from Alma College in Michigan (MI, USA).

About AAPS

American Association of Pharmaceutical Scientists (AAPS) is a non-profit association of more than 7000 scientists and professionals employed in academia, industry, regulatory and other research related to the pharmaceutical sciences worldwide. Its mission is to advance the capacity of pharmaceutical scientists to develop products and therapies that improve global health, which members pursue through four peer-reviewed journals and a variety of events in person and online.

AAPS PharmSci 360 delivers research from across the pharmaceutical continuum, from discovery to delivery, and all stages in between. Thousands of scientists from across the globe converge to discuss cutting-edge breakthroughs, technologies, and techniques in symposia and poster presentations at this science-first event. https://www.aaps.org/pharmsci360.